- MESOX, a spin-out from the pharmaceutics group at Aston Pharmacy School, develops drug carrier technology to improve medicine formulations
- The company won the Start-Up prize at the Medilink Midlands Awards 2024
- The prize is awarded to a new company that shows a promising future.
A spin-out company from Aston University’s pharmaceutics research group has won a medical technology and life sciences industry award.
MESOX, which was founded by Aston University pharmaceutics lecturer Dr Ali Al-Khattawi, won the Medilink Midlands Start-Up Award, which is presented to a newly established company that shows a promising future. The Medilink Midlands Business Awards showcase the best collaborations between industry, academia and the NHS across the Midlands. This year’s ceremony was held at the Athena in Leicester on 9 May.
The awards were established by Medilink Midlands, which provides specialist business support to boost the region’s economic output from the life sciences industry. Working alongside the Midlands Engine and other strategic alliances, it helps stimulate additional and value-added growth of the Midlands as a prosperous community for life sciences.
With in-depth expertise in particle engineering for drug delivery and pharmaceutical spray drying, MESOX uses IP-protected carriers to improve the bioavailability and efficacy of pharmaceuticals, partnering with pharmaceutical and biotechnology companies to bring challenging therapeutics to market.
In its citation, Medilink Midlands described MESOX as “transforming pharmaceutical formulation with its game-changing carrier technologies.”
As a winner of a Medilink Midlands award, MESOX will now be entered into the UK National Awards, the ceremony of which takes place on 11 July 2024 in London.
Dr Al-Khattawi said:
“We are delighted to have won this prestigious award, which highlights the outstanding research and development work being done by the MESOX team and the immense potential of our company to transform the medicine formulation development landscape. Through collaboration with other pharmaceutical companies, clinicians, academic researchers, and by engaging directly with patients to understand their needs, we aim to innovate and advance drug delivery science into life-saving therapeutics.
“At MESOX, our ambition is to be a global, research-based pharmaceutical company rooted in the Midlands, dedicated to developing life-saving therapeutics at speed and resource-efficiency. Our ultimate goal is to enable healthier lives for patients worldwide and ensure better global access to essential medicines.”
- Notes to editors
About Aston University
For over a century, Aston University’s enduring purpose has been to make our world a better place through education, research and innovation, by enabling our students to succeed in work and life, and by supporting our communities to thrive economically, socially and culturally.
Aston University’s history has been intertwined with the history of Birmingham, a remarkable city that once was the heartland of the Industrial Revolution and the manufacturing powerhouse of the world.
Born out of the First Industrial Revolution, Aston University has a proud and distinct heritage dating back to our formation as the School of Metallurgy in 1875, the first UK College of Technology in 1951, gaining university status by Royal Charter in 1966, and becoming the Guardian University of the Year in 2020.
Building on our outstanding past, we are now defining our place and role in the Fourth Industrial Revolution (and beyond) within a rapidly changing world.
For media inquiries in relation to this release, contact Helen Tunnicliffe, Press and Communications Manager, on (+44) 7827 090240 or email: h.tunnicliffe@aston.ac.uk.
Be first to get the latest news, research and expert comment from Aston by following us on X.
Need an expert for your story? Browse our experts directory.